Browsing Tag
Tolmar Inc.
1 post
Rubraca beats docetaxel in TRITON3: FDA clears early-line prostate cancer use for Tolmar
Tolmar’s Rubraca gains FDA approval for BRCA-mutated prostate cancer before chemotherapy. Explore the trial results and what it means for treatment strategy.